Highlighted publications

Ladumor Y, Seong BKA, Hallett R, Valencia-Sama I, Adderley T, Wang Y, Kee L, Gont A, Kaplan DR, Irwin MS.  Vitamin D Receptor activation attenuates Hippo pathway effectors and cell survival in metastatic neuroblastoma.  Mol Cancer Res, 2022 Feb 21:molcanres.0425.2021. doi:10.1158/1541-7786.MCR-21-0425. Online ahead of print.

Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, Ramirez NC, Pfau R, Reshmi S, Wagner E, Nuchtern J, Asgharzadeh S, Shimada H, Maris JM, Bagatell R, Park JR, Hogarty MD.  Revised Neuroblastoma Risk Classification System: A Report From the Children’s Onocology Group.  Journal of Clinical Oncology, 2021 Oct 10;39(29):3229-3241.

Huang H, Gont A, Kee L, Dries R, Pfeifer K, Sharma B, Nebruyne DN, Harlow M, Sengupta S, Guan J, Yeung CM, Wang W, Hallbert, Palmer RH, Irwin MS, and George RE.  Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration.  Cell Reports, 2021 Jul 13;36(2):109363.

Valencia-Sama I, Ladumor Y, Kee L, Adderley T, Christopher G, Robinson CM, Kano Y, Ohh M, Irwin MS.  NRAS status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma.  Cancer Research, 2020 Aug 15;80(16):3413-3423. 

Kano Y, Gebregiworgis T, Marshall CB, Radulovich N, Poon BPK, St-Germain J, Cook JD, Valencia-Sama I, Grant BMM, Herrera SG, Miao J, Raught B, Irwin MS, Lee JE, Yeh JJ, Zhong-Yin Z, Tsao MS, Ikura M, Ohh M.  Tyrosyl phosphorylation of KRAS alters switch I and II conformation and disrupts multiple phases of the GTPase cycle, revealing a therapeutic vulnerability for pancreatic cancer. Nature Communications, 2019 Jan 15;10(1):224.

Alshareef A, Irwin MS, Gupta N, Seong BK, Zhang H, Haquel M, Findlay SD, Rayis M, Al-Dandan S, Lai R.  The absence of a novel intron 19-retaining ALK transcript (ALKI19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients. Oncotarget, 2018 Jan 12;9(12):10698-10713

Seong ABK, Fathers KE, Hallet R, Yung C, Stein L, Mouaaz S, Kee L, Hawkins CE, Irwin MS*, Kaplan DR*.  A Metastatic Mouse Model Identifies Genes that Regulate Neuroblastoma Metastasis. 2017 Feb 1;77(3):696-706 Cancer Research

Marrano P, Irwin MS, Thorner P. Heterogeneity of MYCN amplification at diagnosis, treatment, relapse and metastases. Genes, Chromosomes and Cancer. 2017 Jan;56(1):28-41

Hallet R, Seong, ABK, Kaplan DR*, Irwin MS*. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma. Molecular Oncology, 2016 Nov; 10(9):1461-1472

Seong A, Lau JTML, Adderly, T , Cheng LS, Malkin D, Thorner PS, Irwin MS. SATB2 promotes invasion and migration in osteosarcoma by regulating genes involved in cytoskeleton organization. Oncogene, 2015; 34(27):3582-92

Angelini P, Baruchel, S, Marrano P, Irwin MS, Thorner PS. The neuroblastoma and ganglion components of nodular ganglioneuroblastoma share the same genetic changes, distinct from Schwann cells. Modern Pathology, 2015 Feb; 28(2):166-76

Podkowa M, Irwin MS. Spy’ing on Neuroblastoma Differentiation. Oncotarget (commentary), Aug 2014; 5(15): 5848–5849

Wolter J, Wolter N, Blanch A, Partridge T, Podkowa M, Morgenstern DA, Kaplan DR, Irwin MS. Anti-tumor activity of the beta adrenergic receptor antagonist propranolol in neuroblastoma. Oncotarget, 2014 5(1):161-72

Other publications

Pinto N, Naranjo A, Hibbits E, Kreissman SG, Granger MM, Irwin MS, Bagatell R, London WG, Greengard EG, Park JR, Dubois SG. Predictors of Differential Response to Induction Therapy in High Risk Neuroblastoma: A Report from the Children’s Oncology Group (COG). European Journal of Cancer 2019 Apr 1;112:66-79

Goudie C, Cullinan, N, Villani A, Mathews N, van Engelen K, Malkin D, Irwin MS*^, Foulkes WD*.  A Decision-Support Algorithm for Genetic Referrals for Children with Neuroblastic Tumours. Pediatric Blood and Cancer, 2018 Dec;65(12):e27390

Morgenstern DA, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L, Park JR, Pearson AD, Schleiermacher G, Valteau-Couanet, London WB*, Irwin MS*.  The challenge of defining ‘ultra-high risk neuroblastoma’. Pediatric Blood and Cancer, 2018 Nov 26:e27556. doi: 10.1002/pbc.27556

Depuydt P, Boeva* V, Ambros PF, Asgharzadeh S, Attiyeh E, Cannoodt R, Combaret V, Defferrari R, Fischer M, Hocking TD, Hogarty MD, Irwin MS, Kreissman S, Ladenstein R, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Speleman F, Tonini GP, Valteau-Couanet D, Varesio L, Maris JM, Schleiermacher G**, De Preter K** Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. Journal of National Cancer Institute, 2018 Oct 1;110(10):1084-1093

Naranjo A, Irwin MS, Hogarty MD, Cohn SL, Park JR, London WB. Statistical Framework in Support of a Revised Children’s Oncology Group (COG) Neuroblastoma Risk Classification System. Journal of Clinical Oncology- Clinical Cancer Informatics, 2018, 2:1-15

Alexander N, Sullivan K, Shaikh F, Irwin MS. Characteristics and management of ganglioneuroma and ganglioneuroblastoma-intermixed in children and adolescents.  Pediatric Blood and Cancer, 2018 May; 65(5):e26964

Campbell BB, Light N, Fabrizio D, Zatzman M, de Borja R, Davidson S, Fuligni F, Edwards M, Elvin J, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Hussen K, Wimmer K, Kratz CP, Bowers DC, Laetsch T, Dunn GP, Tanner J, Grimmer MR, Smirnov I, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Cole KA, Oren M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler D, Lindhorst S, Magimairajan V, Constantini S, Toledano H, Elhasid E, Farah R, Dvir R, Dirks P, Huang A, Galati M, Chung B, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A. Comprehensive Analysis of Hypermutation in Human Cancer. Cell. 2017 Nov 16; 171(5):1042-1056

Campbell K, Gastier-Foster J, Mann m, Naranjo A, Van Ryn C. Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, Hogarty MD, Park JR, DuBois S. Association of MYCN Copy Number with Clinical Features, Tumor Biology, and Outcomes in Neuroblastoma: A Report from the Children’s Oncology Group. Cancer, 2017 Nov 1; 123(21):4224-4235

Seibel NL, Janeway K, Allen CE, Chi SN, Cho YJ, Glade-Bender J, Kim A, Laetsch TW, Irwin MS, Takebe N, Tricoli JV, Parsons WD. Pediatric Oncology Enters the Era of Precision Medicine. Current Problems in Cancer: Special Issue on Precision Medicine in Oncology (invited review), 2017 May- Jun; 41(3):194-200

Allen CE, Leatsch T, Mody R, Irwin MS, Lim M, Adamson P, Seibel N, Parsons DW. Cho J, Janeway K on behalf of the Pediatric MATCH Target and Agent Prioritization Committee. Precision Pediatric Oncology: Review of Agents, Target and Rationale for the COG-NCI Pediatric MATCH, Journal of the National Cancer Institute, 2017 May 1;109(5)

Morgenstern DA, London WB, Stephens D, Simon T, Volchenboum S, Ambros P, Shimada H, Ambros PF, Nakagawara A, Matthay K, Cohn SL, Pearson A, Irwin MS.  Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: a study from the International Neuroblastoma (NB) Risk Group (INRG) database. European Journal of Cancer, 2016 Sep;65:1-10. 2016

Owens C*, Li B*, Thomas KE, Irwin MS. Role of Surveillance Imaging and Radiation Exposure in the Detection of Relapsed Neuroblastoma. Pediatric Blood and Cancer, 2016: 63(10):1786-93

Irwin MS, Park JR. Neuroblastoma: Paradigm for Precision Medicine. Pediatric Clinics of North America (review) 2015 62(1):225-56

Morgenstern DA, London WB, Stephens D, Hero B, Volchenboum S, Ambros P, Shimada H, Di Cataldo A, Nakagawara A, Matthay K, Cohn SL, Pearson A, Irwin MS.  Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts improved outcome in patients with stage 4 disease: a study from the International Neuroblastoma (NB) Risk Group (INRG) database Journal of Clinical Oncology, 2014, 32(12):1228-35